PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • The efficacy of an intramedullary nitinol implant in the correction of claw toe or hammertoe deformities

    Payo-Ollero J (1), Casajús-Ortega A (2), Llombart-Blanco R (3), Villas C (3), Alfonso M (3).

    (1) Orthopaedic Surgery and Traumatology Department, Clínica Universidad de Navarra, Av. Pio XII 36, 31008, Pamplona, Spain.
    (2) Faculty of Medicine, Universidad de Navarra, Av. Pio XII 36, 31008, Pamplona, Spain.
    (3) Orthopaedic Surgery and Traumatology Department, Clínica Universidad de Navarra, Av. Pio XII 36, 31008, Pamplona, Spain.

    Archives of Orthopaedic and Trauma Surgery 17 de MAIO de 2019

  • Modified inspiratory muscle training (m-IMT) as promising treatment for gastro-oesophageal reflux disease (GERD)

    Moffa A (1), Oliveto G (2), Matteo FD (3), Baptista P (4), Cárdenas A 5, Cassano M (5), Casale M (2)

    (1) Unit of Otolaryngology, University of Foggia, Foggia, Italy.
    (2) Unit of Otolaryngology, University Campus Bio-Medico, Rome, Italy.
    (3) Unit of Gastroenterology, University Campus Bio-Medico, Rome, Italy.
    (4) Unit of Otolaryngology, University of Navarra, Campus Universitario, Pamplona, Spain.
    (5) Unit of Otolaryngology, University of Foggia, Foggia, Italy.

    Acta Otorrinolaringologica Española 15 de MAIO de 2019

  • Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma

    Vivas I (1), Iribarren K (2), Lozano T (2), Cano D (1), Lasarte-Cia A (2), Chocarro S (2), Gorraiz M (2), Sarobe P (2), Hervás-Stubbs S (2), Bilbao JI (1), Casares N (3), Lasarte JJ (2). (1) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, Avenida Pío XII, 55, 31008, Pamplona, Spain.
    (3) Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, Avenida Pío XII, 55, 31008, Pamplona, Spain.

    Journal of Vascular and Interventional Radiology 14 de MAIO de 2019

  • Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide

    Richardson PG (1), Oriol A (2), Beksac M (3), Liberati AM (4), Galli M (5), Schjesvold F (6), Lindsay J (7), Weisel K (8), White D (9), Facon T (10), San Miguel J (11), Sunami K (12), O'Gorman P (13), Sonneveld P (14), Robak P (15), Semochkin S (16), Schey S (17), Yu X (18), Doerr T (18), Bensmaine A (19), Biyukov T (19), Peluso T (19), Zaki M (18), Anderson K (20), Dimopoulos M (21); OPTIMISMM trial investigators. (1) Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (2) Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
    (3) Ankara University, Ankara, Turkey.
    (4) Università degli studi di Perugia, Perugia, Italy.
    (5) Azienda Ospedaliera Papa Giovanni XXIII, Unità Operativa di Ematologia, Bergamo, Italy.
    (6) Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway; K G Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
    (7) East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.
    (8) Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    (9) Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
    (10) University of Lille, Centre Hospitalier Universitaire Lille, Service des Maladies du Sang, Lille, France.
    (11) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (12) National Hospital Organization Okayama Medical Center, Okayama, Japan.
    (13) Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Trials Ireland, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
    (14) Erasmus MC Cancer Institute, Rotterdam, Netherlands.
    (15) Medical University of Lodz, Lodz, Poland.
    (16) Pirogov Russian National Research Medical University, Moscow, Russia
    (17) Department of Hematology, King's College London, London, UK.
    (18) Celgene Corporation, Summit, NJ, USA.
    (19) Celgene International, Boudry, Switzerland.
    (20) Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (21) National and Kapodistrian University of Athens, Athens, Greece.

    https://www.ncbi.nlm.nih.gov/pubmed/31097405 13 de MAIO de 2019

  • Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

    Perez-Ruiz E (1,2,3,4,5), Minute L (1,2), Otano I (1,2), Alvarez M (1,2), Ochoa MC (1,2,6), Belsue V (1,2), de Andrea C (2,7), Rodriguez-Ruiz ME (1,3), Perez-Gracia JL (2,3,6), Marquez-Rodas I (6,8), Llacer C (9), Alvarez M (5,10,11), de Luque V (5,10), Molina C (1,2), Teijeira A (1,2,6), Berraondo P (12,13,14), Melero I (15,16,17,18,19).

    (1) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (3) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Oncology, Hospital Costa del Sol, Marbella, Spain.
    (5) Instituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria, Málaga, Spain.
    (6) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (7) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
    (8) Department of Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
    (9) Department of Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
    (10) Laboratorio de Biología Molecular del Cáncer, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga, Málaga, Spain.
    (11) Department of Pathology, Faculty of Medicine, Universidad de Málaga, Málaga, Spain.
    (12) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (13) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (14) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (15) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (16) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (17) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (18) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (19) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.

    Nature 01 de MAIO de 2019

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra